Initialising ...
Initialising ...
Initialising ...
Initialising ...
Initialising ...
Initialising ...
Initialising ...
Kaneda, Kazuko*; Shirakami, Yoshifumi*; Kadonaga, Yuichiro*; Watabe, Tadashi*; Oe, Kazuhiro*; Yin, X.*; Haba, Hiromitsu*; Shirasaki, Kenji*; Kikunaga, Hidetoshi*; Tsukada, Kazuaki; et al.
International Journal of Molecular Sciences (Internet), 25(2), p.933_1 - 933_14, 2024/01
Times Cited Count:4 Percentile:89.63(Biochemistry & Molecular Biology)Watabe, Tadashi*; Liu, Y.*; Kaneda, Kazuko*; Sato, Tatsuhiko; Shirakami, Yoshifumi*; Oe, Kazuhiro*; Toyoshima, Atsushi*; Shimosegawa, Eku*; Wang, Y.*; Haba, Hiromitsu*; et al.
International Journal of Molecular Sciences (Internet), 23(16), p.9434_1 - 9434_11, 2022/08
Times Cited Count:12 Percentile:78.96(Biochemistry & Molecular Biology)In this study, we compare the therapeutic effect between [At]NaAt and [
I]NaI. In vitro analysis of double-stranded DNA break (DSB) and colony formation assay were performed using K1-NIS cells. [
At]NaAt induced higher numbers of DSBs and had a reduced colony formation than [
I]NaI. In K1-NIS mice, dose-dependent therapeutic effects were observed in both [
At]NaAt and [
I]NaI. The superior therapeutic effect of [
At]NaAt suggests the promising clinical applicability of targeted alpha therapy using [
At]NaAt in patients with differentiated thyroid cancer refractory to standard [
I]NaI treatment.
Segawa, Mariko; Maeda, Makoto; Toh, Yosuke; Toyoshima, Atsushi*; Shirakami, Yoshifumi*
no journal, ,
no abstracts in English